Pexelizumab

DB04949

biotech investigational

Deskripsi

Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 7.0 hours to 14.5 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Pexelizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Pexelizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Pexelizumab.
Estrone Estrone may increase the thrombogenic activities of Pexelizumab.
Estradiol Estradiol may increase the thrombogenic activities of Pexelizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Pexelizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Pexelizumab.
Mestranol Mestranol may increase the thrombogenic activities of Pexelizumab.
Estriol Estriol may increase the thrombogenic activities of Pexelizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Pexelizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Pexelizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Pexelizumab.
Tibolone Tibolone may increase the thrombogenic activities of Pexelizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Pexelizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Pexelizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Pexelizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Pexelizumab.
Zeranol Zeranol may increase the thrombogenic activities of Pexelizumab.
Equol Equol may increase the thrombogenic activities of Pexelizumab.
Promestriene Promestriene may increase the thrombogenic activities of Pexelizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Pexelizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Pexelizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Pexelizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Pexelizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Pexelizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Pexelizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Pexelizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Pexelizumab.
Formononetin Formononetin may increase the thrombogenic activities of Pexelizumab.
Estetrol Estetrol may increase the thrombogenic activities of Pexelizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pexelizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pexelizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Pexelizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Pexelizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Pexelizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pexelizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pexelizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Pexelizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pexelizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Pexelizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Pexelizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Pexelizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pexelizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pexelizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Pexelizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pexelizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pexelizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Pexelizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pexelizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Pexelizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Pexelizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Pexelizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pexelizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pexelizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Pexelizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Pexelizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Pexelizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Pexelizumab.
Afelimomab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Afelimomab.
Epratuzumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Epratuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bectumomab.
Oregovomab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Oregovomab.
IGN311 The risk or severity of adverse effects can be increased when Pexelizumab is combined with IGN311.
Adecatumumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Adecatumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Labetuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when Pexelizumab is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when Pexelizumab is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when Pexelizumab is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when Pexelizumab is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Pexelizumab is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when Pexelizumab is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when Pexelizumab is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Pexelizumab is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when Pexelizumab is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when Pexelizumab is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Pexelizumab is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when Pexelizumab is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when Pexelizumab is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when Pexelizumab is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Canakinumab.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 10604887
    Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O'Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan SK: Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999 Dec 21-28;100(25):2499-506.
  • PMID: 16569534
    Armstrong PW, Mahaffey KW, Chang WC, Weaver WD, Hochman JS, Theroux P, Rollins S, Todaro TG, Granger CB: Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. Am Heart J. 2006 Apr;151(4):787-90.
  • PMID: 12925454
    Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003 Sep 9;108(10):1184-90. Epub 2003 Aug 18.
  • PMID: 15952913
    Fleisig AJ, Verrier ED: Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass. Expert Opin Biol Ther. 2005 Jun;5(6):833-9.
  • PMID: 16863750
    Haverich A, Shernan SK, Levy JH, Chen JC, Carrier M, Taylor KM, Van de Werf F, Newman MF, Adams PX, Todaro TG, van der Laan M, Verrier ED: Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg. 2006 Aug;82(2):486-92.
  • PMID: 9171898
    Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec;33(17-18):1389-401.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul